Compare CTW & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CTW | ADAG |
|---|---|---|
| Founded | 2013 | 2011 |
| Country | | |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.6M | 90.5M |
| IPO Year | N/A | N/A |
| Metric | CTW | ADAG |
|---|---|---|
| Price | $1.46 | $3.26 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | 53.9K | ★ 253.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | $21.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.10 | $1.30 |
| 52 Week High | $4.88 | $3.46 |
| Indicator | CTW | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 41.89 | 68.34 |
| Support Level | $1.10 | $2.70 |
| Resistance Level | $1.99 | $3.19 |
| Average True Range (ATR) | 0.21 | 0.43 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 34.19 | 85.77 |
CTW Cayman operates the web-based HTML5 gaming platform G123.jp, offering free-to-play games based on Japanese animations, including Queen's Blade, So I'm a Spider, So What?, and Goblin Slayer. The platform features 29 games, with 11 in pre-registration. The Group provides a platform for game developers to generate revenue and reach an international audience through shared revenue from players' in-game purchases. It operates in Japan, Singapore, Taiwan, and China, excluding Taiwan, with the majority of revenue derived from Japan, and has one reporting segment focused on game distribution and related services.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.